Home / Pharmaceuticals / Autoimmune Diseases Treatment Market By Type (Chemical-based Drugs, Biological Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Autoimmune Diseases Treatment Market By Type (Chemical-based Drugs, Biological Drugs) - Growth, Share, Opportunities & Competitive Analysis, 2016 - 2022

Published: May 2016 | Report Code: 57842-05-16

This report on global autoimmune diseases treatment market studies various drugs used for treatment of autoimmune diseases along with pipeline analysis of upcoming potential drugs. Autoimmune diseases (ADs) are a family of more than 80 chronic, and often disabling, illnesses broadly characterized by immune system dysfunction leading to the loss of tolerance to self-antigens, presence of increased level of autoantibodies, inflammatory and mediatory cells and resulting chronic inflammation. Thus, drug pipeline of autoimmune diseases treatment market comprises potential drugs which are more target-specific and possess innovative properties. 

Autoimmune Diseases Treatment Market

For the purpose of this study, the various therapeutic types studied include chemical-based drugs and biological drugs; further, chemical-based are segmented as immunosuppressant drugs, NSAIDs, and corticosteroids. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

The pipeline analysis for autoimmune diseases treatment market comprises projected market sales of Phase III drugs estimated till 2022. There are more than 80 types of clinically different autoimmune diseases. Some of the common types of autoimmune diseases are Hashimoto's thyroiditis, type I diabetes, Crohn's disease, multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis systemic lupus erythematosus, and psoriasis. We have estimated sales of very specific molecules based on the type (chemical-based or biological), disease prevalence, sponsor, depicted peak sales by leading market experts and other factors.

The geographic segmentation of the global autoimmune diseases treatment market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2022 are provided in terms of USD Mn along with the respective CAGRs for the period 2016 to 2022, considering 2015 as the base year.

Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary
2.1 Global Autoimmune Diseases Treatment Market Portaiture
2.2 Global Autoimmune Diseases Treatment Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Autoimmune Diseases Treatment Market, by Geography, 2015 & 2022 (USD Mn)

Chapter 3 Autoimmune Diseases Treatment : Market Dynamics and Outlook
3.1 Autoimmune Diseases Treatment Market Overview
3.1.1 Type of Autoimmune Diseases
3.1.2 Autoimmune Disease Diagnostics
3.1.3 Autoimmune Diseases Treatment : Upcoming Trends and Techniques
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Autoimmune Diseases Treatment Market, 2015 (Value %)

Chapter 4 Global Autoimmune Diseases Treatment Market, By Type of Threapeutic
4.1 Preface
4.2 Chemical-based Drugs
4.2.1 Immunosuppressant Drugs
4.2.2 NSAIDs
4.2.3 Corticosteroids
4.3 Biological Drugs
4.4 Pipeline Analysis
4.4.1 Projected sales of Phase III Drugs estimated till 2022, by Most Prevalent Autoimmune Diseases (US$ Mn)
4.4.1.1 Hashimoto's Thyroiditis
4.4.1.2 Type I Diabetes
4.4.1.3 Crohn's Disease
4.4.1.4 Multiple Sclerosis
4.4.1.5 Rheumatoid Arthritis
4.4.1.5 Ankylosing Spondylitis
4.4.1.5 Systemic Lupus Erythematosus
4.4.1.5 Psoriasis
4.4.2 Tabular Representation of Phase II and I Drugs

Chapter 5 Global Autoimmune Diseases Treatment Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa

Chapter 6 Company Profiles
6.1 Genentech Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Bayer AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.2.4 News Coverage
6.3 Merck & Co.
6.3.1 Business Description
6.3.2 Financial Health and Budget Allocation
6.3.3 Product Portfolio
6.3.4 News Coverage
6.4 Amgen Inc.
6.4.1 Business Description
6.4.2 Financial Health and Budget Allocation
6.4.3 Product Portfolio
6.4.4 News Coverage
6.5 Johnson & Johnson Limited
6.5.1 Business Description
6.5.2 Financial Health and Budget Allocation
6.5.3 Product Portfolio
6.5.4 News Coverage
6.6 Abbott Laboratories
6.6.1 Business Description
6.6.2 Financial Health and Budget Allocation
6.6.3 Product portfolio
6.6.4 News Coverage
6.7 Eli Lilly and Company
6.7.1 Business Description
6.7.2 Financial Health and Budget Allocation
6.7.3 Product Portfolio
6.7.4 News Coverage
6.8 GlaxoSmithKline Plc
6.8.1 Business Description
6.8.2 Financial Health and Budget Allocation
6.8.3 Product Portfolio
6.8.4 News Coverage
6.9 F. Hoffmann-La Roche AG
6.9.1 Business Description
6.9.2 Financial Health and Budget Allocation
6.9.3 Product Portfolio
6.9.4 News Coverage
6.10 Bristol Myers Squibb Company.
6.10.1 Business Description
6.10.2 Financial Health and Budget Allocation
6.10.3 Product Portfolio
6.10.4 News Coverage

List of Figures

FIG. 1 Global Autoimmune Diseases Treatment Market, by Type of Therapeutics, 2015 (USD Mn)
FIG. 2 Relativity Analysis: Global Autoimmune Diseases Treatment Market, by Geography, 2015 & 2022 (USD Mn)
FIG. 3 Attractive Investment Proposition, Global Autoimmune Diseases Treatment Market, 2015
FIG. 4 Market Share Analysis: Global Autoimmune Diseases Treatment Market, 2015 (Value %)
FIG. 5 Global Chemical-Based Drugs Market for Autoimmune Diseases Treatment, 2013 – 2022 (USD Mn)
FIG. 6 Global Biological Drugs Market for Autoimmune Diseases Treatment, 2013– 2022 (USD Mn)
FIG 7 Pipeline Analysis: Global Hashimoto's Thyroiditis Market for Autoimmune Diseases Treatment , Upto 2022 (USD Mn)
FIG 8 Pipeline Analysis: Global Type I Diabetes Market for Autoimmune Diseases Treatment , Upto 2022 (USD Mn)
FIG 9 Pipeline Analysis: Global Crohn's Disease Market for Autoimmune Diseases Treatment , Upto 2022 (USD Mn)
FIG 10 Pipeline Analysis: Global Multiple Sclerosis Market for Autoimmune Diseases Treatment , Upto 2022 (USD Mn)
FIG 11 Pipeline Analysis: Global Rheumatoid Arthritis Market for Autoimmune Diseases , Upto 2022 (USD Mn)
FIG 12 Pipeline Analysis: Global Ankylosing Spondylitis Market for Autoimmune Diseases , Upto 2022 (USD Mn)
FIG 13 Pipeline Analysis: Global Systemic Lupus Erythematosus Market for Autoimmune Diseases , Upto 2022 (USD Mn)
FIG 14 Pipeline Analysis: Global Psoriasis Market for Autoimmune Diseases , Upto 2022 (USD Mn)
FIG 15 Global U.S. Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 16 Global Canada Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG 17 Global U.K Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 18 Global Germany Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 19 Global Rest of Europe Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 20 Global China Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 21 Global Japan Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 22 Global Rest of Asia Pacific Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 23 Global Latin America Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)
FIG. 24 Global Middle East and Africa Autoimmune Diseases Treatment Market Revenue, 2013 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Autoimmune Diseases Treatment Market Revenue, by Type of Therapeutics, 2013 – 2022 (USD Mn)
TABLE 2 Global Autoimmune Diseases Treatment Market Revenue, by Geography, 2013 – 2022 (USD Mn)
TABLE 3 North America Autoimmune Diseases Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 4 Europe Autoimmune Diseases Treatment Market Revenue,by Country, 2013 – 2022 (USD Mn)
TABLE 5 Asia - Pacific Autoimmune Diseases Treatment Market Revenue, by Country, 2013 – 2022 (USD Mn)
TABLE 6 Rest of the World Autoimmune Diseases Treatment Market Revenue, by Region, 2013 – 2022 (USD Mn)

According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease affects up to 50 million Americans. The leading types of autoimmune disorders are type I diabetes mellitus, Grave’s disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, and systemic lupus erythematosus. The autoimmune diseases are expected to be one of the top 10 causes of death in women under the age 65, and are the second highest cause of chronic illness. Further, it is observed as the top cause of morbidity in women in the U.S.

Based on the therapeutics type, the autoimmune diseases treatment market is segmented into:

  • Chemical-based Drugs
    • Immunosuppressant Drugs
    • NSAIDs
    • Corticosteroids
  • Biological Drugs

Autoimmune Diseases Treatment Market 


According to market experts, biologic therapy is increasingly used to treat autoimmune disorders in developed markets, but usage is still low in emerging markets. Biologic therapies have been acknowledged as effective treatments for a variety of autoimmune diseases. However, the associated costs are high due to complex manufacturing processes. In 2012, a study carried out by the National Institute for Health and Care Excellence (NICE) found that in UK biologic drugs cost twenty times as much as conventional therapy. In base year 2015, chemical based drugs accounted for the major market share but during the forecast period 2016 – 2022 biologic drugs are expected to project a significant growth. The key factors assisting the segment growth were with enhanced reimbursement policies have increased the use of biological drugs in developed markets, growing prevalence of autoimmune diseases coupled with growing public awareness, and technological advancements such as the development of novel biomarkers such as Enbrel and Humira.

For the purpose of this study, the global autoimmune diseases treatment market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Autoimmune Diseases Treatment Market

North America was observed as the largest market for autoimmune diseases treatment in the base year 2015 due to growing prevalence of several forms of autoimmune disorders, and presence of government initiatives such as Affordable Care Act and Patient Protection Act. According to the American Autoimmune Related Diseases Association (AARDA), autoimmune disease is one of the top 10 leading causes of death in female children and women in all age groups up to 64 years of age and AARDA also estimates that around 50 million Americans suffer from autoimmune disease. Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies. Dominance of North America and Europe in autoimmune disease market is attributed by factors like rising prevalence of autoimmune diseases, increasing investments in R&D and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about heath care and aging population are going to fuel the rapid growth of autoimmune disease treatment market in Asia-Pacific region in the near future.   

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Credence Webinars

Join Credence analysts to explore the latest IT Trends

view upcoming webinars

Our Clients